Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies.

Endocrine Unit, Department of Medical Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy.
Clinical Endocrinology (Impact Factor: 3.4). 04/2007; 66(3):447-53. DOI: 10.1111/j.1365-2265.2007.02761.x
Source: PubMed

ABSTRACT The aim of this study was to evaluate how resistin and adiponectin (ApN) are involved in maternal energy metabolism and foetal growth.
A cross-sectional study.
Resistin and ApN were measured in 30 healthy nonpregnant women, 73 pregnant women [10-41 weeks of gestation; 18 with gestational diabetes mellitus (GDM), five with pregnancy-induce hypertension (PIH), nine with pre-eclampsia (PE), eight with chronic hypertension (CH) and 33 normal] and 40 foetal samples (20-41 weeks of gestation; 18 from GDM mothers and 22 from normal mothers).
Resistin levels were significantly higher in normal pregnant women than in nonpregnant controls (13.7 +/- 2.1 vs. 6.3 +/- 1.6 ng/ml; P < 0.005) and showed a negative correlation with gestational age (P < 0.0001, r = -0.7). Only women with PE presented resistin levels significantly lower than normotensive women of the same gestational age (8.2 +/- 1.2 vs. 17.9 +/- 4.3 ng/ml; P < 0.005). ApN levels, although similar in normal pregnant women to those in nonpregnant controls, were significantly lower in women with GDM (37-41 weeks; 5.2 +/- 0.5 vs. 8.2 +/- 0.8 mg/l; P < 0.0001) and PE (20-37 weeks; 5.0 +/- 0.7 vs. 9.5 +/- 0.7 mg/l; P = 0.008) than those found in normal women matched for gestational age. Resistin was detected in the umbilical venous blood in foetuses from 20 to 41 weeks of gestation. In all newborns, both resistin and ApN levels were significantly higher than those recorded in adult life and did not correlate with maternal levels (P = ns, r = 0.03 for resistin and P = ns, r = -0.3 for ApN). Foetuses from diabetic mothers had ApN significantly lower than normal foetuses (26.8 +/- 2.6 vs. 37.5 +/- 3.5 mg/l; P = 0.02), while resistin levels were similar (17.3 +/- 3.7 vs. 18.2 +/- 1.5 ng/ml; P = ns).
The secretion pattern of ApN in normal and complicated pregnancies strongly suggests an involvement of ApN in insulin resistance during gestation, while resistin seems to have a minor role. Moreover, the detection of high levels of resistin and ApN in cord blood during gestation is consistent with a regulatory action of these adipokines on tissue differentiation and foetal growth.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating adipokines are associated with physiological and pathophysiological processes in both obesity and pregnancy. Obesity in pregnancy increases the risk of pregnancy complications and the majority of research uses body mass index (BMI) to assess fatness. Specific fat compartments are associated with obesity-induced health risks yet it is not known how abdominal fat mass in pregnancy is related to circulating adipokines. Plasma leptin, resistin, visfatin, and adiponectin were measured by immunoassay in healthy pregnant women of normal weight (BMI 18.5–24.9; n = 17) and overweight/obese pregnant women (BMI 25.0–40.0, n = 21) in the third trimester. Total body fat and abdominal subcutaneous and visceral fat mass were measured at 1–3 weeks postpartum. Overweight/obese women had greater total body fat (t = −6.210, P < 0.001) and abdominal subcutaneous fat (t = –5.072, P < 0.001) than normal-weight women while there was no difference in abdominal visceral fat. Overweight/obese women had higher leptin (66.3 ± 34.2 vs. 35.7 ± 19.3 ng/mL, P < 0.001) compared with normal-weight women. Leptin was associated with total body fat (r = 0.782, P < 0.001) and resistin was associated with abdominal visceral fat (r = 0.452, P = 0.045). No significant correlations were observed between adiponectin or visfatin and any measure of body composition. In pregnant women, resistin has the potential to be a circulating biomarker for visceral fat, an ectopic fat compartment. These observational data may provide insight for the pathophysiological roles of adipokines and the impact of visceral fat in pregnant women.
    Adipocyte. 10/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The placental vasculature rapidly expands during the course of pregnancy in order to sustain the growing needs of the fetus. Angiogenesis and vascular growth are stimulated and regulated by a variety of growth factors expressed in the placenta or present in the fetal circulation. Like in tumors, hypoxia is a major regulator of angiogenesis because of its ability to stimulate expression of various proangiogenic factors. Chronic fetal hypoxia is often found in pregnancies complicated by maternal diabetes as a result of fetal hyperglycaemia and hyperinsulinemia. Both are associated with altered levels of hormones, growth factors, and proinflammatory cytokines, which may act in a proangiogenic manner and, hence, affect placental angiogenesis and vascular development. Indeed, the placenta in diabetes is characterized by hypervascularisation, demonstrating high placental plasticity in response to diabetic metabolic derangements. This review describes the major regulators of placental angiogenesis and how the diabetic environment in utero alters their expression. In the light of hypervascularized diabetic placenta, the focus was placed on proangiogenic factors.
    BioMed Research International 01/2014; 2014:145846. · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to compare serum maternal adiponectin concentrations in pregnant women with isolated intrauterine growth retardation (IUGR) and in pregnant women with IUGR concomitant with pre-eclampsia (IUGRcwPE).
    Journal of the Turkish German Gynecological Association. 01/2014; 15(3):173-6.

Full-text (2 Sources)

Available from
Sep 2, 2014